Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Related Posts

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank

Kim HS, Rezaee-Zavareh MS, Wang Y, Attia AM, Kwak M, Burm S, Celtik D, Legaspi D, Khattab O, Kim N, Mengistu BM, Larios KN, Kim[...]

The association of eicosanoids with lung structure and function: Findings from the Multi-Ethnic Study of Atherosclerosis lung study and Framingham Heart Study

Ambatipudi M, McNeill JN, Roshandelpoor A, Alotaibi M, Mounsey LA, Hoffman E, O'Connor G, Choi SH, Allen NB, Barr RG, Jain M, Cheng S, Ho[...]

Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0

Varghese C, Dachs N, Schamberg G, Abell T, Al-Haddad M, Angeli-Gordon TR, Ayazi S, Ayubi H, Bashashati M, Bulat R, Calder S, Cederwall CB, Chang[...]